Sanofi AB
Lindhagensgatan 120 
Box 30052
104 25 Stockholm 

Telefon: 08-634 50 00
Kontakta oss

Lantus, effekt upp till 24 timmar!

Dokumentation för Lantus®

Endast för vårdpersonal!

  • Skriv ut
  • Larger Smaller


  • Uppdaterad : 2016-02-26

Nedan finns en sammanställning av dokumentation för Lantus.

PK/PD studier

Lepore et al. Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of Long-Acting Human Insulin Analog Glargine, NPH Insulin, and Ultralente Human Insulin and Continuous Subcutaneous Infusion of Insulin Lispro. Diabetes, Vol. 49, December 2000.

Porcellati et al. Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1-Diabetes. Diabetes Care, Vol 30, No 10, October 2007.

Typ 1-diabetesstudier

Ratner etl al. Less Hypoglycemia With Insulin Glargine in Intensive Insulin Therapy for Type 1-Diabetes. Diabetes Care 23:639–643, 2000.

Porcellati et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1-diabetes mellitus given meal-time lispro insulin. Diabetic Medicine, 21, 1213–1220, 2004.

Hamann et al.  A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1-Diabetes. Diabetes Care, Vol 26, No 6, June 2003.

Fulcher et al. Glargine is superior to neutral protamine Hagedorn improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Internal Medicine Journal 2005; 35: 536-542.

Hershon et al. Once-daily insulin Glargine compared with twice-daily NPH insulin in patients with type 1-diabetes. Endocrine Practice Vol 10 No 1 Jan/feb 2004.

Kabadi et al. Deleterious Outcomes after Abrupt Transition from Insulin Glargine to Insulin Detemir in Patients with Type 1-Diabetes Mellitus. Clin Drug Invest 2008; 28 (11).

Typ 2-diabetesstudier

Janka et al. Comparison of Basal Insulin Added to Oral Agents Versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes. Diabetes Care, Vol 28, No 2, Feb 2005.

Fritsche et al. Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2-Diabetes. Annals of Internal Medicine, Volume 138, Number 12, 2003.

Davies et al. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2-Diabetes. Diabetes Care, Vol 28, No 6, June 2005.

Rosenstock et al. Reduced Hypoglycemia Risk With Insulin Glargine. Diabetes Care, Vol 28, No 4, April 2005.

Riddle et al. The Treat-to-Target Trial. Diabetes Care, Vol 26, No 11, November 2003.

Rosenstock et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2-diabetes. Diabetologia (2008) 51:408–416.

Schreiber et al. The Long-term efficacy of insulin Glargine plus Oral antidiabetic agents in a 32-month observational study of everyday clinical practice. Diabetes Technology and Therapeutics 2008 Apr;10(2):121-7.

Yki-Järvinen et al. Initiate Insulin by Aggressive Titration and Education (INITIATE). Diabetes Care, Vol 30, No 6, June 2007.